A consortium of investors led a $110m Series D funding round in Orchestra BioMed, a biomedical company, with participation from Medtronic, RTW Investments, Perceptive Advisors, Terumo and SternAegis. “RTW is proud to lead these transactions, which we believe will enable Orchestra BioMed to further advance its BackBeat CNT and Virtue SAB programs. A recent double-blind, randomized pilot study published in the Journal of the American Heart Association (JAHA)1 showed that BackBeat CNT drove statistically significant and clinically meaningful reductions in blood pressure in its target patient population. These data support Orchestra BioMed’s plans to further investigate the potential for this therapy via a global pivotal study in collaboration with Medtronic. With two partnered programs expected to commence pivotal trials in 2023, we believe Orchestra BioMed is poised for success,” Roderick Wong, RTW Investments Managing Partner and CIO.